Sector News

Lonza to expand development services for mammalian products in Singapore

October 10, 2021
Life sciences

Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced it will invest to expand mammalian development services in Singapore. The expansion will establish additional capacity for cell culture, purification, and analytical services for mammalian biologics.

The increased service capabilities complement the existing offering, consisting of cell line construction services, process development and process characterization services at the mammalian and cell therapy manufacturing site in Singapore.

This investment will expand the current laboratory capabilities by establishing a new 1,800m2 laboratory at Singapore Science Park, increasing the headcount of the mammalian development services team in Singapore to 125 employees. The new laboratory began operations in September. As part of the investment, the existing laboratories at Lonza’s Tuas, Singapore site will be upgraded by the end of 2021.

Jeetendra Vaghjiani, Senior Director of Clinical Development for Mammalian Biologics, Lonza, commented: “The growth of our global manufacturing network brought a need to increase services supporting these assets. The investment to expand our mammalian manufacturing services in Singapore will ensure that our team continues to deliver timely support to our customers, in particular for process development and characterization studies necessary for advancing therapies towards regulatory approvals and commercialization.”

As part of the expansion, Lonza will invest in the latest technology for mammalian process and analytical development through the addition of systems for cell line development, the latest in perfusion and process analytical technology for process development, as well as providing the capability to perform extensive characterization of biopharmaceuticals using mass spectrometry for the first time in Singapore. The investment will also provide opportunities to expand the service offering and strengthen the position for the anticipated market growth in complex protein formats.

The addition of new technology, alongside the increase in capacity and headcount of Lonza’s development services team in Singapore, will provide a comprehensive offering for small- and large-scale GMP mammalian manufacturing services and cell therapy capabilities.

By Lonza, Press Release

Source: lonza.com

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.